Skip to content
Home › Funds › General Atlantic
Venture capital · Q3 2026 13F recap

General Atlantic: Q3 2026 13F

Growth equity firm.

Holdings as of Sep 30, 2026 (Q3 2026)Filed Nov 13, 202613F deadline Nov 16, 2026 (45 days after quarter end)

$2.5B
stocks & ETFs (13F)
12
positions
1
new positions
1
sold out
—
options (notional)
PostLinkedIn

Portfolio at a glance

Largest stock and ETF positions sized by weight, coloured by change since the previous 13F.

DLO · Dlocal: 20.4% · TrimmedDLO20.4%CHYM · Chime: 20.3% · TrimmedCHYM20.3%LFTO · Liftoff Mobile: 16.1% · UnchangedLFTO16.1%XP · Xp, Inc: 15.2% · TrimmedXP15.2%ALKT · Alkami: 10.7% · UnchangedALKT10.7%SPTX · Seaport Therapeutics: 5.0% · UnchangedSPTX5.0%RSKD · Riskified: 3.4% · Added toRSKD3.4%NRIX · Nurix Therapeutics: 2.9% · UnchangedNRIX2.9%PHVS · Pharvaris: 2.1% · TrimmedPHVS2.1%PBLS · Parabilis Medicines: 2.0% · UnchangedPBLS2.0%KRSA · Korsana: 1.8% · NewKRSAGROV · Grove Collaborative: 0.1% · Unchanged
Box size = share of the reported portfolio.TrimmedUnchangedAdded toNew

Biggest moves

Estimated dollars bought and sold in Q3 2026 (change in shares × quarter-end price).

◀ SoldBought ▶
  • KRSANEW+$44M
  • RSKD+$42M
  • PHVS−$155M
  • DLO−$135M
  • RVMDOUT−$67M
  • CHYM−$62M
  • XP−$55M

Top buys

Ranked by estimated dollars added: change in shares × quarter-end price.

General Atlantic top buys
StockChangeEst. $
KRSA
Korsana
New+$44M
RSKD
Riskified
Added+100%+$42M

Top sales

Ranked by estimated dollars sold, including full exits.

General Atlantic top sales
StockChangeEst. $
PHVS
Pharvaris
Trimmed-74.8%−$155M
DLO
Dlocal
Trimmed-21.1%−$135M
Revolution Medicines
Sold out−$67M
Chime
Trimmed-11%−$62M
XP
Xp, Inc
Trimmed-12.7%−$55M

New positions

StockChangeEst. $
KRSA
Korsana
New+$44M

Sold out

StockChangeEst. $
Revolution Medicines
Sold out−$67M

Largest holdings

Top 12 of 12 stock and ETF positions, as of Sep 30, 2026. Options are listed separately below.

StockChangeValue
DLO
Dlocal
Trimmed-21.1%$507M
Chime
Trimmed-11%$504M
LFTO
Liftoff Mobile
Unchanged$400M
XP
Xp, Inc
Trimmed-12.7%$377M
ALKT
Alkami
Unchanged$265M
SPTX
Seaport Therapeutics
Unchanged$123M
RSKD
Riskified
Added+100%$84M
NRIX
Nurix Therapeutics
Unchanged$72M
PHVS
Pharvaris
Trimmed-74.8%$52M
PBLS
Parabilis Medicines
Unchanged$50M
KRSA
Korsana
New$44M
GROV
Grove Collaborative
Unchanged$3M

Source: GENERAL ATLANTIC, L.P., Form 13F-HR on SEC EDGAR, compared with the filing for Jun 30, 2026. 13F shows only US-listed long positions (plus listed options), is delayed up to 45 days, and estimated dollar changes assume the quarter-end price. Not investment advice. How we calculate this.

All 110 funds → · Q3 2026 recap of every fund →

Weekly digest · free

13F filings and guru moves, in one short email

A Sunday digest of what famous investors said and filed this week, plus an alert when someone changes stance. Free, no spam, unsubscribe anytime.